2015
DOI: 10.1016/j.prp.2014.12.013
|View full text |Cite
|
Sign up to set email alerts
|

Intratumoral CD68-, CD117-, CD56-, and CD1a-positive immune cells and the survival of Iranian patients with non-metastatic intestinal-type gastric carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
8
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 27 publications
1
8
0
Order By: Relevance
“…Therefore, it may nonetheless be a relatively reliable TAM marker. Nine of the 12 included studies used CD68 as a macrophage marker (Ishigami et al, 2003;Ohno et al, 2005;Haas et al, 2009;Kawahara et al, 2010;Amoueian et al, 2015;Kim et al, 2015;Wu et al, 2015;Zhang et al, 2015Zhang et al, , 2016. The corresponding pooled HR indicated that high levels of CD68 + TAMs correlated with poor OS, but no significant correlation was identified between such cells and DFS.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…Therefore, it may nonetheless be a relatively reliable TAM marker. Nine of the 12 included studies used CD68 as a macrophage marker (Ishigami et al, 2003;Ohno et al, 2005;Haas et al, 2009;Kawahara et al, 2010;Amoueian et al, 2015;Kim et al, 2015;Wu et al, 2015;Zhang et al, 2015Zhang et al, , 2016. The corresponding pooled HR indicated that high levels of CD68 + TAMs correlated with poor OS, but no significant correlation was identified between such cells and DFS.…”
Section: Discussionmentioning
confidence: 99%
“…The full texts of 15 candidate articles were carefully reviewed, with three being excluded as a result (two with inadequate data and one having examined the same patient group as another study). Finally, 12 studies were included in the meta-analysis ( Figure 1; Ishigami et al, 2003;Ohno et al, 2005;Haas et al, 2009;Kawahara et al, 2010;Wang et al, 2011;Amoueian et al, 2015;Kim et al, 2015;Lin et al, 2015;Wu et al, 2015;Park et al, 2016;Zhang et al, 2015Zhang et al, , 2016. In total, 1388 patients from China, Taiwan, Korea, Iran, Japan, and Germany were included.…”
Section: Study Characteristicsmentioning
confidence: 99%
See 2 more Smart Citations
“…Recent studies have suggested that the loss of DCs would correlate with tumor progression, lower survival rate, and poor prognosis for patients affected by different human neoplasms, possibly as a consequence of a deficit in the host immune response to tumor growth and a cytotoxic T lymphocytes impairment . This was shown to be true for patients affected by colorectal , gastric , pancreatic , breast , and other human cancers, as well as in experimental animal models . Because of these clinically relevant findings, some DC‐based cancer immunotherapies have been developed, but a meaningful clinical response remains to be achieved .…”
Section: Discussionmentioning
confidence: 99%